116 related articles for article (PubMed ID: 4050740)
1. A phase II trial of PCNU in patients with malignant melanoma and central nervous system metastases.
Feldman LD; Feun LG; Benjamin RS; Yap BS; Plager C; Papadopoulos N; Savaraj N; Burgess MA; Bodey GP
Am J Clin Oncol; 1985 Jun; 8(3):215-7. PubMed ID: 4050740
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of PCNU in advanced malignant melanoma: an Eastern Cooperative Oncology Group pilot study.
Earhart RH; Muggia FM; Golomb FM
Invest New Drugs; 1985; 3(3):297-301. PubMed ID: 4066223
[TBL] [Abstract][Full Text] [Related]
3. Fotemustine plus dacarbazine for malignant melanoma.
Avril MF; Bonneterre J; Cupissol D; Grob JJ; Kalis B; Fumoleau P; Kerbrat P; Israel L; Fargeot P; Lambert D
Eur J Cancer; 1992; 28A(11):1807-11. PubMed ID: 1389514
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of fotemustine in patients with metastatic malignant melanoma.
Falkson CI; Falkson G; Falkson HC
Invest New Drugs; 1994; 12(3):251-4. PubMed ID: 7896545
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of intracarotid PCNU.
Stewart DJ; Grahovac Z; Russel NA; Hugenholtz H; Gupta S; Benoit BC; Richard MT; Maroun JA; Hopkins HS; Locke L
J Neurooncol; 1987; 5(3):245-50. PubMed ID: 3681387
[TBL] [Abstract][Full Text] [Related]
6. Phase II trail of PCNU in refractory advanced breast cancer.
Kavanagh JJ; Yap HY; Blumenschein GR; Stewart D; Bodey GP
Am J Clin Oncol; 1982 Jun; 5(3):249-51. PubMed ID: 7081144
[TBL] [Abstract][Full Text] [Related]
7. PCNU in the treatment of recurrent medulloblastoma and ependymoma--a POG Study.
Ragab AH; Burger P; Badnitsky S; Krischer J; Van Eys J
J Neurooncol; 1986; 3(4):341-2. PubMed ID: 3958779
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
Jacquillat C; Khayat D; Banzet P; Weil M; Avril MF; Fumoleau P; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
Cancer Chemother Pharmacol; 1990; 25(4):263-6. PubMed ID: 2403853
[TBL] [Abstract][Full Text] [Related]
9. Fotemustine plus dacarbazine in advanced stage III malignant melanoma.
Binder M; Winkler A; Dorffner R; Glebowski E; Wolff K; Pehamberger H
Eur J Cancer; 1992; 28A(11):1814-6. PubMed ID: 1389516
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of PCNU in advanced renal cell carcinoma and malignant melanoma.
Harvey JH; Smith FP; Bowers MW; Neefe JR; Butler TP; Gullo JJ; Schertz G; Lokey J; Schein PS; Woolley PV
Cancer Treat Rep; 1984; 68(7-8):1049-50. PubMed ID: 6744340
[No Abstract] [Full Text] [Related]
11. PCNU: phase II evaluation in advanced colorectal carcinoma.
Pazdur R; Samson MK; Baker LH
Invest New Drugs; 1988 Jun; 6(2):93-5. PubMed ID: 3170134
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
Chang J; Atkinson H; A'Hern R; Lorentzos A; Gore ME
Eur J Cancer; 1994; 30A(14):2093-5. PubMed ID: 7857710
[TBL] [Abstract][Full Text] [Related]
13. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.
Jacquillat C; Khayat D; Banzet P; Weil M; Fumoleau P; Avril MF; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
Cancer; 1990 Nov; 66(9):1873-8. PubMed ID: 2224783
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
Creagan ET; Ahmann DL; Schutt AJ; Green SJ
Cancer Treat Rep; 1982 Jun; 66(6):1425-6. PubMed ID: 7083244
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of PCNU administered by 5-day courses.
Earhart RH; Koeller JM; Davis HL
Cancer Treat Rep; 1981; 65(9-10):835-40. PubMed ID: 7273016
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of PCNU in advanced colorectal carcinoma. An Eastern Cooperative Oncology Group pilot study.
Earhart RH; Moertel C; Hahn RG; Woodhouse CL; Ramirez G; Engstrom PF
Am J Clin Oncol; 1984 Aug; 7(4):309-12. PubMed ID: 6741861
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in recurrent malignant brain tumors.
Feun LG; Stewart DJ; Leavens ME; Burgess MA; Savaraj N; Benjamin RS; Bodey GP
J Neurooncol; 1983; 1(1):45-8. PubMed ID: 6678305
[TBL] [Abstract][Full Text] [Related]
18. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
[TBL] [Abstract][Full Text] [Related]
19. PCNU and recurrent childhood brain tumors.
Allen JC; Hancock C; Walker R; Tan C
J Neurooncol; 1987; 5(3):241-4. PubMed ID: 3681386
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of PCNU.
Kalman LA; Gralla RJ; Casper ES; Kris MG; Gordon C; Woodcock TM
Cancer Treat Rep; 1983 Nov; 67(11):1027-9. PubMed ID: 6315229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
